Liver fibrosis develops when repeated injury from conditions such as chronic viral hepatitis, alcohol-related liver disease or metabolic dysfunction-associated steatohepatitis (MASH) triggers a persistent wound-healing response. Hepatic stellate cells, which normally store vitamin A, become activated and produce collagen and other material that accumulates as scar tissue. Fibrosis can regress, particularly when the underlying injury is addressed, but it can also progress to cirrhosis. Treatment options remain limited, and researchers are looking for ways to interrupt scar formation directly. Earlier studies linked SNAI1 to fibrosis in several organs, leaving open how it controls stellate cell activity in the liver and whether targeting it could slow scarring.
A study (DOI: 10.48130/targetome-0026-0060) published in Targetome on 11 November 2026 by Zhao-Qiu Wu's team, China Pharmaceutical University, reports that SNAI1 activates two genes involved in scarring and that genetic deletion or pharmacological inhibition of SNAI1 reduces liver fibrosis in mice.
The researchers first analyzed publicly available gene expression data from human liver samples, including single-cell RNA sequencing data that allowed them to pinpoint which cells expressed SNAI1. Its expression rose in hepatic stellate cells in fibrotic livers. Reporter mice and tests on cells isolated from mouse livers likewise showed that SNAI1 was abundant in stellate cells and increased during fibrosis. To test whether the protein contributed to scarring, the team deleted Snai1 selectively in mouse stellate cells and induced liver injury with carbon tetrachloride. Compared with control mice exposed to the same chemical, these mice had lower blood levels of two enzymes associated with liver injury, fewer signs of stellate cell activation and less collagen in liver tissue. In cultured human stellate cells, the researchers used reporter assays to measure gene activity and chromatin immunoprecipitation to determine where SNAI1 bound to DNA. SNAI1 bound to the regulatory regions of ACTA2, a marker of stellate cell activation, and COL1A1, which encodes a component of type I collagen. Its binding was accompanied by increased histone acetylation, a chemical modification associated with greater gene activity. The team then tested LFW273, which lowered SNAI1 protein levels and reduced the expression of both genes in cultured cells. In mice, oral LFW273 reduced liver injury and collagen deposition when given during chemical exposure, including when treatment began three weeks after exposure started. In a second model, mice fed a diet deficient in methionine and choline developed fatty liver and fibrosis. Both LFW273 and the comparison drug resmetirom reduced liver fat, collagen deposition and markers of stellate cell activation in that model.
Together, the experiments link SNAI1 activity in stellate cells to collagen accumulation and show that lowering SNAI1 levels can ease scarring even after liver injury has begun in mice. The diet-based model captures some features of MASH, including liver fat and fibrosis, while missing metabolic features of the human disease such as insulin resistance. Further studies will need to assess whether the effects persist in models that more closely reflect human MASH and whether an optimized compound can achieve longer exposure at a lower dose. Safety and effectiveness in people remain to be established.
Source:
Journal reference:
Pan, C., et al. (2026). Genetic and pharmacological targeting of SNAI1 attenuates liver fibrosis in mice. Targetome. DOI: 10.48130/targetome-0026-0060. https://www.maxapress.com/article/doi/10.48130/targetome-0026-0060